Vicarious Surgical Announces Planned Retirement of Chief Operating Officer
Vicarious Surgical (NYSE: RBOT) announced that Chief Operating Officer John Mazzola will retire effective April 1, 2025, after nearly 40 years in healthcare manufacturing, supply chain, and quality control. Mazzola's responsibilities will transition to Company President Randy Clark.
According to CEO Adam Sachs, Mazzola has been key in developing manufacturing processes, enhancing product quality control, and strengthening supply chain resilience. The company states it is well-positioned for its next phase, including upcoming first clinical use cases and pivotal trial.
Vicarious Surgical (NYSE: RBOT) ha annunciato che il Direttore Operativo John Mazzola si ritirerà a partire dal 1 aprile 2025, dopo quasi 40 anni nel settore della produzione sanitaria, della catena di approvvigionamento e del controllo qualità. Le responsabilità di Mazzola saranno trasferite al Presidente dell'azienda, Randy Clark.
Secondo il CEO Adam Sachs, Mazzola è stato fondamentale nello sviluppo dei processi di produzione, nel miglioramento del controllo qualità dei prodotti e nel rafforzamento della resilienza della catena di approvvigionamento. L'azienda afferma di essere ben posizionata per la sua prossima fase, che include i prossimi casi clinici e trial decisivi.
Vicarious Surgical (NYSE: RBOT) anunció que el Director de Operaciones John Mazzola se retirará a partir del 1 de abril de 2025, después de casi 40 años en la fabricación de atención médica, la cadena de suministro y el control de calidad. Las responsabilidades de Mazzola se transferirán al Presidente de la empresa, Randy Clark.
Según el CEO Adam Sachs, Mazzola ha sido clave en el desarrollo de procesos de fabricación, en la mejora del control de calidad del producto y en el fortalecimiento de la resiliencia de la cadena de suministro. La empresa afirma que está bien posicionada para su próxima fase, que incluye los próximos casos de uso clínico y ensayos cruciales.
Vicarious Surgical (NYSE: RBOT)는 운영 책임자인 John Mazzola가 의료 제조, 공급망 및 품질 관리 분야에서 거의 40년의 경력을 쌓은 후 2025년 4월 1일부로 은퇴한다고 발표했습니다. Mazzola의 책임은 회사의 사장인 Randy Clark에게 이관됩니다.
CEO Adam Sachs에 따르면 Mazzola는 제조 프로세스 개발, 제품 품질 관리 강화 및 공급망 회복력 강화를 위한 핵심 인물이었습니다. 이 회사는 향후 임상 사용 사례와 중대한 시험을 포함한 다음 단계에 잘 준비되어 있다고 밝혔습니다.
Vicarious Surgical (NYSE: RBOT) a annoncé que le directeur des opérations John Mazzola prendra sa retraite à compter du 1er avril 2025, après près de 40 ans dans la fabrication de soins de santé, la chaîne d'approvisionnement et le contrôle qualité. Les responsabilités de Mazzola seront transférées au président de l'entreprise, Randy Clark.
Selon le PDG Adam Sachs, Mazzola a joué un rôle clé dans le développement des processus de fabrication, l'amélioration du contrôle de qualité des produits et le renforcement de la résilience de la chaîne d'approvisionnement. L'entreprise indique qu'elle est bien positionnée pour sa prochaine phase, qui comprend les prochains cas d'utilisation clinique et les essais décisifs.
Vicarious Surgical (NYSE: RBOT) gab bekannt, dass der Chief Operating Officer John Mazzola zum 1. April 2025 in den Ruhestand gehen wird, nachdem er fast 40 Jahre in der Gesundheitsproduktion, der Lieferkette und der Qualitätskontrolle tätig war. Mazzolas Verantwortlichkeiten werden an den Unternehmenspräsidenten Randy Clark übergeben.
Laut CEO Adam Sachs war Mazzola entscheidend für die Entwicklung von Produktionsprozessen, die Verbesserung der Produktqualität und die Stärkung der Resilienz der Lieferkette. Das Unternehmen erklärt, dass es gut positioniert ist für die nächste Phase, die bevorstehende klinische Anwendungsfälle und entscheidende Studien umfasst.
- Company reports being well-positioned for upcoming clinical use cases and pivotal trial
- Planned orderly transition of COO responsibilities to existing Company President indicates continuity
- Loss of experienced executive with 40 years of healthcare manufacturing expertise
“On behalf of the entire organization, I want to express our sincere gratitude to John for his exceptional leadership and dedication over the past few years,” said Adam Sachs, Co-Founder and Chief Executive Officer. “John has been instrumental in developing and streamlining our corporate manufacturing processes, enhancing our product quality control, and strengthening our supply chain resilience; as a result, Vicarious Surgical is well-positioned for its next chapter as we prepare for our upcoming first clinical use cases and pivotal trial. We are deeply grateful for his contributions and wish him a happy and fulfilling retirement.”
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next generation robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside Vicarious Surgical’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of Vicarious Surgical’s Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of Vicarious Surgical’s initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of Vicarious Surgical to raise financing in the future; the success, cost and timing of Vicarious Surgical’s product and service development activities; the potential attributes and benefits of Vicarious Surgical’s product candidates and services; Vicarious Surgical’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; Vicarious Surgical’s ability to identify, in-license or acquire additional technology; Vicarious Surgical’s ability to maintain its existing license, manufacture, supply and distribution agreements; Vicarious Surgical’s ability to compete with other companies currently marketing or engaged in the development of products and services that Vicarious Surgical is currently marketing or developing; the size and growth potential of the markets for Vicarious Surgical’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of Vicarious Surgical’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; Vicarious Surgical’s financial performance; economic downturns, political and market conditions and their potential to adversely affect Vicarious Surgical’s business, financial condition and results of operations; Vicarious Surgical’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in Vicarious Surgical’s filings with the SEC. Vicarious Surgical cautions that the foregoing list of factors is not exclusive. The company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vicarious Surgical does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218953518/en/
Investor:
Kaitlyn Brosco
Vicarious Surgical
Kbrosco@vicarioussurgical.com
Media:
media@vicarioussurgical.com
Source: Vicarious Surgical Inc.
FAQ
When will Vicarious Surgical COO John Mazzola retire?
Who will take over Vicarious Surgical COO responsibilities after John Mazzola's retirement?
What are the next major milestones for Vicarious Surgical (RBOT)?
What were John Mazzola's main contributions to Vicarious Surgical (RBOT)?
